{"filing":{"accession_number":"0001437749-26-019196","cik":"0001719406","ticker":"NRXPW","company_name":"NRX Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"nrxp20260602_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1719406/000143774926019196/nrxp20260602_8k.htm"},"events":[{"id":7556,"run_id":6641,"accession_number":"0001437749-26-019196","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"NRx Pharmaceuticals announced an underwritten public offering of common stock on June 2, 2026. While the disclosure is preliminary (announcing intent rather than completion), a registered public offering of equity is a material dilutive issuance that would affect shareholder ownership and is disclosed under Item 8.01 (Other Events). The announcement of intent to conduct such an offering is material to investors assessing capital structure and dilution risk.","company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXPW","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3692,"accession_number":"0001437749-26-019196","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"NRx Pharmaceuticals announced an underwritten public offering of common stock on June 2, 2026. While the disclosure is preliminary (announcing intent rather than completion), a registered public offering of equity is a material dilutive issuance that would affect shareholder ownership and is disclosed under Item 8.01 (Other Events). The announcement of intent to conduct such an offering is material to investors assessing capital structure and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:40:34.244381+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3692,"accession_number":"0001437749-26-019196","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"NRx Pharmaceuticals announced an underwritten public offering of common stock on June 2, 2026. While the disclosure is preliminary (announcing intent rather than completion), a registered public offering of equity is a material dilutive issuance that would affect shareholder ownership and is disclosed under Item 8.01 (Other Events). The announcement of intent to conduct such an offering is material to investors assessing capital structure and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:40:34.244381+00:00","company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXPW","filing_date":"2026-06-02"}]}